RxDoctor Payments Data

Amy Smith

Family · Jeffersonville, INNPI 1528620044

Payments from drug & device makers

$452in general payments, 2019–2025

Across 32 payments — averaging $14.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Urovant Sciences Inc$125
  • Avanir Pharmaceuticals, Inc.$70
  • Novartis$69
  • Tactile Systems Technology Inc$42
  • Sumitomo Pharma America, Inc.$35
  • Integra Lifesciences Corporation$32
  • plus $77 from 4 others

What the payments were for

  • Food & beverage$44097%
  • Education$123%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$452 in reported general payments places this provider in the 50th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$187,932
Medicare patients
362
Services billed
2,129

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban177$65,127
SantylCollagenase Clostridium Hist.36$36,397
TrulicityDulaglutide33$34,257
JardianceEmpagliflozin51$17,305
ErtapenemErtapenem Sodium42$16,322
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog72$15,375
XareltoRivaroxaban15$13,669
Risperdal ConstaRisperidone Microspheres12$11,714
Tresiba Flextouch U-200Insulin Degludec42$11,458
Fiasp FlextouchInsulin Aspart (Niacinamide)35$11,312
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen465$10,929
LinzessLinaclotide19$10,675
GemtesaVibegron33$10,528
BelsomraSuvorexant50$8,037
Lacosamide35$7,396

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$32$34,25733 claims
Sumitomo Pharma America, Inc.Gemtesa$35$10,52833 claims
NovartisEntresto$69$6,60719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 4,392 family providers in Indiana.

Other family in Jeffersonville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →